On February 12, 2020 Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, reported that Dr. Klaus Paulini, Chief Executive Officer of Aeterna, will present at NobleCon16 – Noble Capital Markets’ 16th Annual Investor Conference on Monday, February 17th at 11:30 a.m. ET in Hollywood, Florida (Press release, AEterna Zentaris, FEB 12, 2020, View Source [SID1234554204]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
As part of his presentation, Dr. Paulini will provide a corporate overview and update on the Company’s lead product, Macrilen (macimorelin), the only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Dr. Paulini’s slide presentation will be made available on the Company’s website on Monday, February 17th.
In addition to the presentation, management will be available to participate in investor meetings with registered qualified investors attending the conference. To request a meeting, please contact the NobleCon16 one-on-one desk